Cryptosporioptide A (Compound 3), a protein tyrosine phosphatase inhibitor, originates from the insect-parasitic fungus Cordyceps gracilioides. This compound effectively inhibits several enzymes including PTP1B, SHP2, CDC25B, LAR, and SHP1 with respective IC50 values of 7.3, 5.7, 7.6, >50, and 4.9 μg/mL [1].

Managlinat dialanetil (MB06322) is an orally available and potent fructose 1,6-bisphosphatase (FBPase) inhibitor with hypoglycaemic activity for the study of type 2 diabetes.

β-Glycerophosphate disodium salt pentahydrate is a protein phosphatase inhibitor.

Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability. vutiglabridin ameliorates mptp-induced neurodegeneration in Parkinson's disease mice by targeting mitochondrial paraoxonase-2. Vutiglabridin is a clinical phase 2 drug for the treatment of obesity and has therapeutic effects on p-mitochondrial PON2 in a PD model. vutiglabridin penetrates the brain, binds PON2, and restores 1-methyl-4-phenylpyridine (MPP*)-induced neuroblastoma in SH-SY5Y Vutiglabridin significantly attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dyskinesia and dopaminergic neuronal damage in mice modeled with PD in mouse experiments.

2-Bromo-4'-hydroxyacetophenone(PTP Inhibitor I) is a cell-permeable, protein tyrosine phosphatase (PTP) inhibitor that covalently blocks the catalytic domain of the Src homology region 2 domain-containing phosphatase (SHP-1(ΔSH2)) with a Ki value of 43 μM and PTP1B with a Ki value of 42 μM [1]. SHP-1 and PTP1B both have known roles in regulating insulin signaling as well as myeloid and lymphoid cell differentiation, making inhibitors of these phosphatases of interest in diabetes, cancer, allergy, and inflammation research [2].